FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1298-1301 March 20, 2008 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Bhatt, D. L. Related Article by Wiviott, S. D. PubMed Citation

To the Editor: Wiviott et al. (Nov. 15 issue)¹ report the pivotal results of the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON–TIMI) 38. To better assess the advantage of prasugrel over clopidogrel with respect to the benefit:risk ratio, two important clinical issues should be clarified. Since the numbers of deaths were nearly identical in the prasugrel group (154 deaths) and the clopidogrel group (155 deaths), as were the numbers of strokes, and since for each death from cardiovascular causes prevented by the use of prasugrel, one additional episode of fatal . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.